Bluejay Diagnostics, INC DEF 14A proxy statements

Bluejay Diagnostics, Inc. has provided a 2025 mid-year business and corporate update, highlighting progress in its SYMON-II clinical study for sepsis diagnostics, ongoing manufacturing efforts, and recent financial activities including a capital raise and cost-saving measures, while facing substantial losses and Nasdaq listing challenges.

Bluejay Diagnostics is holding its annual meeting on June 18, 2025, to vote on director elections, reverse stock splits, and the ratification of its accounting firm.

Bluejay Diagnostics has amended its bylaws to reduce the quorum requirement for its upcoming Special Meeting of Stockholders to one-third of the shares entitled to vote.

Bluejay Diagnostics is asking stockholders to approve a reverse stock split to meet Nasdaq's minimum bid price requirement and potentially attract a broader range of institutional investors.

Bluejay Diagnostics is holding a special meeting to seek stockholder approval for increasing authorized shares and ratifying the issuance of Class C and Class D warrants related to a recent offering.

Bluejay Diagnostics is asking stockholders to vote on proposals including increasing authorized shares and implementing a reverse stock split at its annual meeting on May 14, 2024.